Abstract
A brief historical introduction describes early attempts to silence specific genes using the antisense oligonucleotides that flourished in the 1980s. Early aspirations for therapeutic applications were almost extinguished by the unexpected complexity of oligonucleotide pharmacology. Once the biochemistry and molecular biology behind some of the pharmacology was worked out, new approaches became apparent for using oligonucleotides to treat disease. The biochemistry of small nucleic acids is outlined in Section 2. Various approaches employing oligonucleotides to control cellular functions are reviewed in Section 3. These include antisense oligonucleotides and siRNA that bind to RNA, antigene oligonucleotides that bind to DNA, and aptamers, decoys, and CpG oligonucleotides that bind to proteins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zamecnik, P. C., & Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences USA 75, 280–284.
Stephenson, M. L., & Zamecnik, P. C. (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Sciences USA 75, 285–288.
Zamecnik, P., Goodchild, J., Taguchi, Y., & Sarin, P. S. (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proceedings of the National Academy of Sciences USA 83, 4143–4146.
Wilson, T. J., & Lilley, D. M. (2009) The evolution of ribozyme chemistry. Science 232, 1436–1438.
Breaker, R. R. (2008) Complex riboswitches. Science 319, 1795–1797.
Ghildiyal, M., & Zamore, P. D. (2009) Small silencing RNAs: An expanding universe. Nature Reviews Genetics 10, 94–108.
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20.
Moazed, D. (2009) Small RNAs in transcriptional gene silencing and genome defence. Nature 457, 413–420.
Carthew, R. W., & Sontheimer, E. J. (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642–655.
Vasudevan, S., Tong, Y., & Steitz, J. A. (2007) Switching from repression to activation: MicroRNAs can up-regulate translation. Science 318, 1931–1934.
Dolgin, E. (2009) Now showing: RNA activation. The Scientist 23, 34–39.
Farazi, T. A., Juranek, S. A., & Tuschl, T. (2008) The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development 135, 1201–1214.
Olejniczak, M., Galka, P., & Krzyzosiak, W. J. (2010) Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Research 38, 1–16.
Lee, H.-C., et al. (2009) qiRNA is a new type of small interfering RNA induced by DNA damage. Nature 459, 274–277.
Ku, G., & McManus, M. T. (2008) Behind the scenes of a small RNA gene-silencing pathway. Human Gene Therapy 19, 17–26.
Marquez, R. T., & McCaffrey, A. P. (2008) Advances in MicroRNAs: Implications for gene therapists. Human Gene Therapy 19, 27–38.
Bonauer, A., et al. (2009) MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324, 1710–1713.
Williams, A. H., et al. (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326, 1549–1554.
Amaral, P. P., Dinger, M. E., Mercer, T. R., & Mattick, J. S. (2008) The eukaryotic genome as an RNA machine. Science 319, 1787–1789.
Pennisi, E. (2009) Some RNA may play key role in repressing genes, slowing cancer. Science 324, 1252–1253.
Morris, K. V. (2009) RNA-directed transcriptional gene silencing and activation in human cells. Oligonucleotides 19, 299–305.
Hawkins, P. G., Santoso, S., Adams, C., Anest, V., & Morris, K. V. (2009) Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Research 37, 2984–2995.
Schwartz, J., et al. (2008) Antisense transcripts are targets for activating small RNAs. Nature Structural & Molecular Biology 15, 842–848.
Panter, G., Kužnik, A., & Jerala, R. (2009) Therapeutic applications of nucleic acids as ligands for toll-like receptors. Current Opinion Molecular Therapeutics 11, 133–145.
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Research 36, 4158–4171.
Juliano, R., Bauman, J., Kang, H., & Ming, X. (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Molecular Pharmaceutics 6, 686–695.
Stein, C. A., et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Research 38, e3.
Rudnick, S. I., Swaminathan, J., Sumaroka, M., Liebhaber, S., & Gewirtz, A. M. (2008) Effects of local mRNA structure on posttranscriptional gene silencing. Proceedings of the National Academy of Sciences 105, 13787–13792.
Ichihara, M., et al. (2007) Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. Nucleic Acids Research 35, e123.
Kauffmann, A. D., Campagna, R. J., Bartels, C. B., & Childs-Disney, J. L. (2009) Improvement of RNA secondary structure prediction using RNase H cleavage and randomized oligonucleotides. Nucleic Acids Research 37, e121.
Li, Z., Fortin, Y., & Shen, S.-H. (2009) Forward and robust selection of the most potent and noncellular toxic siRNAs from RNAi libraries. Nucleic Acids Research 37, e8.
Gifford, L. K., et al. (2005) Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules. Nucleic Acids Research 33, e28.
Perkel, J. M. (2009) RNAi therapeutics: A two-year update. Science 326, 454–456.
Lanford, R. E., et al. (2010) Therapeutic silencing of MicroRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198–201.
Hashizume, R., et al. (2008) New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro-oncol 10, 112–120.
Lu, Y., et al. (2009) A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Research 37, e24.
Medina, P. P., & Slack, F. J. (2009) Inhibiting microRNA function in vivo. Nature Methods 6, 37–38.
Horwich, M. D., & Zamore, P. D. (2008) Design and delivery of antisense oligonucleotides to block microRNA function in cultured drosophila and human cells. Nature Protocols 3, 1537–1549.
Trang, P., et al. (2009) Regression of murine lung tumors by the let-7 microRNA. Oncogene 29, 1580–1587.
Koizumi, M. (2006) ENA® oligonucleotides as therapeutics. Current Opinion Molecular Therapeutics 8, 144–149.
Mitsuoka, Y., et al. (2009) A bridged nucleic acid, 2',4'-BNACOC: Synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2',4'-BNACOC monomers and RNA-selective nucleic-acid recognition. Nucleic Acids Research 37, 1225–1238.
Ørum, H., & Wengel, J. (2001) Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Current Opinion Molecular Therapeutics 3, 239–243.
Rottman, F., Dunlap, B. E., & Friderici, K. H. (1971) 2'-O-methyl polynucleotides as templates for cell-free amino acid incorporation. Biochemistry 10, 2581–2587.
Iversen, P. L., & Newbry, S. (2005) Manipulation of zebrafish embryogenesis by phosphorodiamidate morpholino oligomers indicates minimal non-specific teratogenesis. Current Opinion Molecular Therapeutics 7, 104–108.
Boutimah-Hamoudi, F., et al. (2007) Cellular antisense activity of peptide nucleic acid (PNAs) targeted to HIV-1 polypurine tract (PPT) containing RNA. Nucleic Acids Research 35, 3907–3917.
Bramsen, J. B., et al. (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Research 37, 2867–2881.
Thiel, K. W., & Giangrande, P. H. (2009) Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19, 209–222.
Collingwood, M. A., et al. (2008) Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18, 187–200.
Hickerson, R. P., et al. (2008) Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 18, 345–354.
Querbes, W., et al. (2009) Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. Oligonucleotides 19, 23–29.
Kalluri, R., & Kanasaki, K. (2008) Generic block on angiogenesis. Nature 452, 543–544.
Robbins, M., Judge, A., & MacLachlan, I. (2009) siRNA and innate immunity. Oligonucleotides 19, 89–101.
Kenworthy, R., et al. (2009) Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Research 37, 6587–6599.
Olejniczak, M., Galka, P., & Krzyzosiak, W. J. (2009) Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Research 38, 1–16.
Kleinman, M. E., et al. (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591–597.
Khan, A. A., et al. (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotechnology 27, 549–555.
Grimm, D., et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537–541.
Goodchild, J. (2000) Hammerhead ribozymes: Biochemical and chemical considerations. Current Opinion Molecular Therapeutics 2, 272–281.
Müller-Kuller, T., Capalbo, G., Klebba, C., Engels, J. W., & Klein, S. A. (2009) Identification and characterization of a highly efficient anti-HIV pol hammerhead ribozyme. Oligonucleotides 19, 265–271.
Schlosser, K., & Li, Y. (2009) Biologically inspired synthetic enzymes made from DNA. Chemistry & Biology 16, 311–322.
Schlosser, K., & Li, Y. (2009) DNAzyme-mediated catalysis with only guanosine and cytidine nucleotides. Nucleic Acids Research 37, 413–420.
Reyes-Gutiérrez, P., & Alvarez-Salas, L. M. (2009) Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes. Oligonucleotides 19, 233–242.
Beane, R., Gabillet, S., Montaillier, C., Arar, K., & Corey, D. (2008) Recognition of chromosomal DNA inside cells by locked nucleic acids. Biochemistry 57, 13147–13149.
Beane, R., et al. (2007) Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. Biochemistry 46, 7572–7580.
Hu, J., & Corey, D. R. (2007) Inhibiting gene expression with peptide nucleic acid (PNA)–peptide conjugates that target chromosomal DNA. Biochemistry 46, 7581–7589.
Duca, M., Vekhoff, P., Oussedik, K., Halby, L., & Arimondo, P. B. (2008) The triple helix: 50 years later, the outcome. Nucleic Acids Research 36, 5123–5138.
Liu, Y., Nairn, R. S., & Vasquez, K. M. (2009) Targeted gene conversion induced by triplex-directed psoralen interstrand crosslinks in mammalian cells. Nucleic Acids Research 37, 6378–6388.
Fraunfelder, F. W. (2005) Pegaptanib for wet macular degeneration. Drugs of Today 41, 703–709.
Blake, C. M., Sullenger, B. A., Lawrence, D. A., & Fortenberry, Y. M. (2009) Antimetastatic potential of PAI-1–Specific RNA aptamers. Oligonucleotides 19, 117–128.
Huang, Y.-F., et al. (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 10, 862–868.
Mallikaratchy, P., Tang, Z. W., & Tan, W. H. (2008) Cell specific aptamer-photosensitizer conjugates as a molecular tool in photodynamic therapy. ChemMedChem 3, 425–428.
Cao, Z., et al. (2009) Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angewandte Chemie International Edition English 48, 6494–6498.
Levy-Nissenbaum, E., Radovic-Moreno, A. F., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2008) Nanotechnology and aptamers: Applications in drug delivery. Trends in Biotechnology 26, 442–449.
Zhou, J., et al. (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of dicer substrate siRNAs into HIV infected cells. Nucleic Acids Research 37, 3094–3109.
Hunsicker, A., et al. (2009) An RNA aptamer that induces transcription. Chemistry & Biology 16, 173–180.
Kang, J., Lee, M. S., Copland, J. A., Luxon, B. A., & Gorenstein, D. G. (2008) Combinatorial selection of a single standed DNA thioaptamer from whole cell selection. Chemistry – A European Journal 14, 1769–1775.
Tomita, N., Morishita, R., Tomita, T., & Ogihara, T. (2002) Potential therapeutic applications of decoy oligonucleotides. Current Opinion Molecular Therapeutics 4, 166–170.
Tomita, N., et al. (2003) Development of novel decoy oligonucleotides: Advantages of circular dumb-bell decoy. Current Opinion Molecular Therapeutics 5, 107–112.
Crinelli, R., Bianchi, M., Gentilini, L., Palma, L., & Magnani, M. (2004) Locked Nucleic Acids (LNA): Versatile tools for designing oligonucleotide decoys with high stability and affinity. Current Drug Targets 5, 745–52.
Warncke, S., Gégout, A., & Carell, T. (2009) Phosphorothioation of oligonucleotides strongly influences the inhibition of bacterial (M.HhaI) and human (Dnmt1) DNA methyltransferases. ChemBioChem 10, 728–734.
Krieg, A. M. (2006) Therapeutic potential of toll-like receptor 9 activation. Nature Reviews Drug Discovery 5, 471–484.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Goodchild, J. (2011). Therapeutic Oligonucleotides. In: Goodchild, J. (eds) Therapeutic Oligonucleotides. Methods in Molecular Biology, vol 764. Humana Press. https://doi.org/10.1007/978-1-61779-188-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-61779-188-8_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-187-1
Online ISBN: 978-1-61779-188-8
eBook Packages: Springer Protocols